Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study among Children, Adolescents and Adults Newly Diagnosed with Autism
- Resource Type
- Journal Articles
Reports - Research
- Authors
- Shoaib, Azza (ORCID 0000-0002-6976-2594); Cepeda, M. Soledad; Murray, Gayle; Ochs-Ross, Rachel
- Source
- Journal of Autism and Developmental Disorders. Oct 2022 52(10):4311-4320.
- Subject
- Autism Spectrum Disorders
Comorbidity
Attention Deficit Hyperactivity Disorder
Emotional Disturbances
Intervention
Behavior Modification
Drug Therapy
Children
Adolescents
Adults
- Language
- English
- ISSN
- 0162-3257
1573-3432
We used real world data to summarize comorbidities and interventions among patients newly diagnosed with autism spectrum disorder (ASD). Data were derived from two claims-based US healthcare databases; Medicaid and Optum to construct a retrospective cohort of 36,000 patients. Attention-Deficit-Hyperactivity-Disorder (ADHD) was the most common co-morbidity (Medicaid: 50.09%; Optum: 44.16%), followed by mood disorder (Medicaid: 16.56% and Optum: 17.47%). Most patients received at least one type of treatment. Behavioral therapy was common (74.64% in Medicaid and 71.97% in Optum). More than half the cohorts received at least 1 pharmacotherapy. However, pharmacotherapies were diverse. Combination therapy and therapy switching was common. Understanding the clinical diversity and complexity of patients with ASD is an important first step in understanding unmet therapeutic needs.